MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have follicular lymphoma that is CD20-positive (a specific marker on tumor cells), grade 1, 2, or 3a
- Your lymphoma is not responding to rituximab (rituximab-refractory)
- Your health status is fair enough for treatment (ECOG score 0 to 2)
- You have at least one measurable tumor spot on a CT scan (size meets the trial’s minimum measurements)
- You can safely take study medicines (blood counts are adequate) and you can give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether MIL62 combined with lenalidomide can shrink or control follicular lymphoma or marginal zone (MZ) lymphoma that has come back or not responded to earlier treatment. It’s designed for adults with measurable disease and enough body strength to take part.
This trial tests a new drug, IMM0306, combined with lenalidomide for people with follicular lymphoma that has come back or stopped responding to at least two prior treatments. The goal is to see if adding IMM0306 helps more than lenalidomide alone.
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Hear when a new Follicular Lymphoma and Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.